Show simple item record

dc.contributor.authorReuter, A
dc.contributor.authorTisile, P
dc.contributor.authorvon Delft, D
dc.contributor.authorCox, H
dc.contributor.authorCox, V
dc.contributor.authorDitiu, L
dc.contributor.authorGarcia-Prats, A
dc.contributor.authorKoenig, S
dc.contributor.authorLessem, E
dc.contributor.authorNathavitharana, R
dc.contributor.authorSeddon, JA
dc.contributor.authorStillo, J
dc.contributor.authorvon Delft, A
dc.contributor.authorFurin, J
dc.date.accessioned2018-05-17T14:27:56Z
dc.date.available2018-05-17T14:27:56Z
dc.date.issued2017-11-01
dc.date.submitted2018-05-16
dc.identifier.citationThe devil we know: is the use of injectable agents for the treatment of MDR-TB justified? 2017, 21 (11):1114-1126 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920
dc.identifier.pmid29037291
dc.identifier.doi10.5588/ijtld.17.0468
dc.identifier.urihttp://hdl.handle.net/10144/619139
dc.description.abstractFor decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.rightsArchived with thanks to The International Journal of Tuberculosis and Lung Diseaseen
dc.titleThe devil we know: is the use of injectable agents for the treatment of MDR-TB justified?en
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen
refterms.dateFOA2019-03-04T13:54:48Z
html.description.abstractFor decades, second-line injectable agents (IAs) have been the cornerstone of treatment for multidrug-resistant tuberculosis (MDR-TB). Although evidence on the efficacy of IAs is limited, there is an expanding body of evidence on the serious adverse events caused by these drugs. Here, we present the results of a structured literature review of the safety and efficacy of IAs. We review the continued widespread use of these agents in the context of therapeutic alternatives-most notably the newer TB drugs, bedaquiline and delamanid-and from the context of human rights, ethics and patient-centered care. We conclude that there is limited evidence of the efficacy of IAs, clear evidence of the risks of these drugs, and that persons living with MDR-TB should be informed about these risks and provided with access to alternative therapeutic options.


Files in this item

Thumbnail
Name:
Reuter et al - 2017 - The devil ...
Size:
238.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record